

SUPPLEMENTARY MATERIAL

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

Authors: Jeffrey Frankel, MD,¹ David Staskin, MD,² Susann Varano, MD,³ Michael Kennelly, MD,⁴ Diane K. Newman, DNP, ANP-BC,⁵ Matt T. Rosenberg, MD,⁶ Rachael A. Jankowich, RN, MSN,^{7*} Denise Shortino, MS,^{7*} Paul N. Mudd Jr, PharmD, MBA,^{7*} Cynthia J. Girman, DrPH, FISPE⁸

¹Seattle Urology Research Center, Seattle, WA, USA; ²Tufts University School of Medicine, Boston, MA, USA; ³Clinical Research Consulting, Milford, CT, USA; ⁴Carolinas Medical Center, Charlotte, NC, USA; ⁵Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; ⁶Mid-Michigan Health Centers, Jackson, MI, USA; ⁷Urovant Sciences, Irvine, CA, USA; ⁸CERobs Consulting, LLC, Chapel Hill, NC, USA

*At the time the study was conducted.

Corresponding Author: Cynthia J. Girman, DrPH, FISPE

CERobs Consulting, LLC

2612 Lumina Avenue North

Wrightsville Beach, NC 28480

cindy.girman@cerobs.com

1-910-679-8023

Supplementary Table 1. Change From Baseline at Week 12 in Average Daily Number of Micturitions, Urgency Episodes, and UUI Episodes by PGI-Change* (Pooled Across Treatment Groups)

	N	Mean Change (SD)	Mean % Change (SD)	Median Change	Median % Change
Micturitions					
Much better	430	-2.49 (2.32)	-21.51 (18.48)	-2.29	-21.86
Moderately better	303	-1.95 (2.76)	-15.65 (23.16)	-2.00	-18.18
A little better	337	-1.68 (2.58)	0.23 (241.30)	-1.50	-12.95
No change or worse	263	-0.70 (2.74)	-4.71 (19.31)	-0.57	-4.96
Urgency episodes					
Much better	430	-3.74 (3.38)	-52.62 (41.30)	-3.15	-60.89
Moderately better	303	-2.76 (3.76)	-27.64 (123.32)	-2.29	-35.00
A little better	337	-2.19 (3.44)	-15.45 (112.47)	-1.68	-24.14
No change or worse	263	-0.95 (3.49)	-8.15 (44.50)	-0.57	-8.83
UUI episodes[†]					
Much better	341	-2.54 (2.24)	-77.87 (60.57)	-2.00	-93.17
Moderately better	227	-1.71 (2.46)	-45.83 (65.67)	-1.33	-64.49
A little better	272	-1.47 (2.16)	-33.55 (74.73)	-1.00	-44.12
No change or worse	191	-0.69 (2.35)	6.40 (159.99)	-0.61	-22.31

FAS, full analysis set; FAS-I, FAS for incontinence; PGI-C, Patient Global Impression of Change; UUI, urge urinary incontinence.

*Presented in the FAS (all randomized patients who took ≥ 1 dose of double-blind study treatment and had ≥ 1 evaluable change from baseline micturition measurement).

[†]Presented in the FAS-I (all randomized patients who took ≥ 1 dose of double-blind study treatment and had ≥ 1 evaluable change from baseline measurement for UUI episodes).